Serum microRNA-193b as a promising biomarker for prediction of chemoradiation sensitivity in esophageal squamous cell carcinoma patients

  • Authors:
    • Chung Man Chan
    • Kenneth K. Y. Lai
    • Enders K. O. Ng
    • Mei Na Kiang
    • Tiffany W. H. Kwok
    • Hector K. Wang
    • Kwok Wah Chan
    • Tsz Ting Law
    • Daniel K. Tong
    • Kin Tak Chan
    • Nikki P. Lee
    • Simon Law
  • View Affiliations

  • Published online on: December 27, 2017     https://doi.org/10.3892/ol.2017.7698
  • Pages: 3273-3280
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Esophageal squamous cell carcinoma (ESCC) is the most predominantly occurring type of esophageal cancer worldwide. Locally advanced ESCC patients are treated by neoadjuvant chemoradiation for tumor downstaging prior to tumor resection. Patients receiving this treatment have an increased expectation of cure via the following tumor resection and have better survival outcomes. However, not all patients respond well to chemoradiation and poor responders suffer from treatment‑associated toxicity and complications without benefits. No method is currently available to predict patient chemoradiation response and to exclude poor responders from ineffective treatment. To address this clinical limitation, the present study aimed to identify non‑invasive biomarkers for predicting patient chemoradiation response. Due to the features of microRNA (miRNA) in cancer diagnosis, prognosis and treatment response prediction, serum miRNA arrays were performed to identify potential miRNA(s) that may be used for chemoradiation response prediction in ESCC. Using an miRNA array to compare pre‑treatment serum sample pools from 10 good responders and 10 poor responders, the present study identified miR‑193b, miR‑942 and miR‑629* as candidate miRNAs for predicting chemoradiation response. Subsequent validation using reverse transcription‑quantitative polymerase chain reaction confirmed that miR‑193b, however not miR‑942 and miR‑629*, were significantly increased in sera from 24 good responders, compared with 23 poor responders. Further analyses using the receiver operating characteristic curve revealed a strong predictive power of serum miR‑193b on discriminating good responders from poor responders to chemoradiation. In addition, a high serum level of miR‑193b was significantly associated with better survival outcomes. Therefore, serum miR‑193b may be considered a promising biomarker for predicting chemoradiation response and post-therapy survival of ESCC patients.
View Figures
View References

Related Articles

Journal Cover

March-2018
Volume 15 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Chan CM, Lai KK, Ng EK, Kiang MN, Kwok TW, Wang HK, Chan KW, Law TT, Tong DK, Chan KT, Chan KT, et al: Serum microRNA-193b as a promising biomarker for prediction of chemoradiation sensitivity in esophageal squamous cell carcinoma patients. Oncol Lett 15: 3273-3280, 2018.
APA
Chan, C.M., Lai, K.K., Ng, E.K., Kiang, M.N., Kwok, T.W., Wang, H.K. ... Law, S. (2018). Serum microRNA-193b as a promising biomarker for prediction of chemoradiation sensitivity in esophageal squamous cell carcinoma patients. Oncology Letters, 15, 3273-3280. https://doi.org/10.3892/ol.2017.7698
MLA
Chan, C. M., Lai, K. K., Ng, E. K., Kiang, M. N., Kwok, T. W., Wang, H. K., Chan, K. W., Law, T. T., Tong, D. K., Chan, K. T., Lee, N. P., Law, S."Serum microRNA-193b as a promising biomarker for prediction of chemoradiation sensitivity in esophageal squamous cell carcinoma patients". Oncology Letters 15.3 (2018): 3273-3280.
Chicago
Chan, C. M., Lai, K. K., Ng, E. K., Kiang, M. N., Kwok, T. W., Wang, H. K., Chan, K. W., Law, T. T., Tong, D. K., Chan, K. T., Lee, N. P., Law, S."Serum microRNA-193b as a promising biomarker for prediction of chemoradiation sensitivity in esophageal squamous cell carcinoma patients". Oncology Letters 15, no. 3 (2018): 3273-3280. https://doi.org/10.3892/ol.2017.7698